INS and type 1 diabetes mellitus: In a phase 1b open-label dose-finding study, it was found to reduce the percentage of circulating Th17, Th1, and Th17.1 cells and proinsulin-specific T cells that secreted IFN-γ and IL-17A and be safe for use in adults with T1D (26).